1000342-95-9|4-Bromo-6-(trifluoromethyl)-1H-indazole| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 1000342-95-9 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 1000342-95-9 ]

CAS No. :	1000342-95-9
Formula :	C₈H₄BrF₃N₂
M.W :	265.03
SMILES Code :	FC(F)(F)C1=CC(Br)=C2C=NNC2=C1
MDL No. :	MFCD09026956
InChI Key :	JRUCLQINUHVRJW-UHFFFAOYSA-N
Pubchem ID :	24729232

Safety of [ 1000342-95-9 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 1000342-95-9 ] Show Less

Physicochemical Properties

Num. heavy atoms	14
Num. arom. heavy atoms	9
Fraction Csp3	0.12
Num. rotatable bonds	1
Num. H-bond acceptors	4.0
Num. H-bond donors	1.0
Molar Refractivity	48.8
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	28.68 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.47
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	3.13
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	4.5
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.9
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.65
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	3.13

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.86
Solubility	0.0362 mg/ml ; 0.000137 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-3.4
Solubility	0.105 mg/ml ; 0.000397 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-4.65
Solubility	0.00592 mg/ml ; 0.0000223 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.69 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<0.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.76

Application In Synthesis of [ 1000342-95-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1000342-95-9 ]

[ 1000342-95-9 ] Synthesis Path-Downstream 1~35

1
[ 110-87-2 ]
[ 1000342-95-9 ]
[ 1425932-71-3 ]

Yield	Reaction Conditions	Operation in experiment
78%	With toluene-4-sulfonic acid; In tetrahydrofuran; for 18h;Inert atmosphere; Reflux;	Referential example 25 (l-(Tetrahydro-2H-pyran-2-yl)-6-(trifluoromethyl)-lH-indazol-4-yl)methanamine (127) step 1 : A round-bottom flask was charged with 4-bromo-6-(trifluoromethyl)-lH-indazole (1.00 g, 3.8 mmol), TsOH monohydrate (27 mg, 0.15 mmol), 3,4-dihydro-2H-pyran (1.59 g, 18.9 mmol), and THF (25 mL). The reaction mixture was degassed with nitrogen and heated under reflux for 18 h, and then the solvent was removed in vacuo. The residue was purified by S1O2 chromatography to afford 4-bromo-l - (tetrahydro-2H-pyran-2-yl)-6-(trifluoromethyl)-lH-indazole (1.03 g, 78percent) as a yellow oil. MS (ESI) m/z: 265.2 [(M - THP group)+l]+.

References: [1]Patent: WO2013/26914,2013,A1 .Location in patent: Page/Page column 122.

2
[ 1000342-95-9 ]
[ 1425932-73-5 ]

References: [1]Patent: WO2013/26914,2013,A1 .

3
[ 1000342-95-9 ]
[ 1425932-72-4 ]

References: [1]Patent: WO2013/26914,2013,A1 .

4
(4-((2-hydroxyethyl)carbamoyl)phenyl)boronic acid [ No CAS ]
[ 1000342-95-9 ]
[ 76-05-1 ]
[ 1454293-91-4 ]

Yield	Reaction Conditions	Operation in experiment
30%		EXAMPLE 130: N-(2-hydroxyethyl)-4-(6-(trifiuoromethyl)-lH-indazol-4- yl)benzamide [0550] A vial was charged with a mixture of 4-bromo-6-(trifluoromethyl)-lH-indazole (0.300 g, 1.132 mmol), (4-((2-hydroxyethyl)carbamoyl)phenyl)boronic acid (0.237 g, 1.132 mmol) and PdCl2(dppf) (0.041 g, 0.057 mmol) in dioxane (10 mL) and aqueous saturated NaHC03 (3 mL). The resulting yellow suspension was heated at 140°C for 60 minutes in a microwave reactor. The reaction mixture was subsequently concentrated and the crude residue was purified by preparative HPLC, eluting with 40percent> ACN (containing 0.035percent) TFA) in H20 (containing 0.05percent TFA) over a period of 4.5 minutes. The product-containing fractions were combined and volatiles removed in vacuo to give a TFA salt of the title compound as white solid (0.12 g, 30percent). 1H NMR (400 MHz, CD3OD) delta ppm 3.56 (t, J=5.81 Hz, 2 H), 3.75 (t, J=5.81 Hz, 2 H), 7.49 (d, J=1.01 Hz, 1 H), 7.78-7.89 (m, 2 H), 7.93 (s, 1 H), 8.00-8.10 (m, 2 H), 8.21-8.32 (m, 1 H); ESI-MS m/z [M+H]+ calc'd for Ci7Hi4F3N302, 350.1; found 350.1.

References: [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0549; 0550.

5
[ 1000342-95-9 ]
[ 76-05-1 ]
[ 628692-15-9 ]
4-(2-methoxypyrimidin-5-yl)-6-(trifluoromethyl)-1H-indazole trifluoroacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
39%		EXAMPLE 246: 4 2-methoxypyrimidin-5-yl)-6-(trifluoromethyl)-lH-indazole [0784] A vial was charged with a mixture of 4-bromo-6-(trifluoromethyl)-lH-indazole (0.1 g, 0.377 mmol), (2-methoxypyrimidin-5-yl)boronic acid (0.076 g, 0.491 mmol) and PdCl2(dppf) (0.014 g, 0.019 mmol) in dioxane (8 mL) and aqueous saturated NaHC03 (2 mL). The resulting light brown suspension was heated at 140°C for 45 minutes in a microwave reactor. The reaction mixture was subsequently concentrated and the crude residue was purified by preparative HPLC, eluting with a gradient of 35-40percent ACN (containing 0.035percent TFA) in H20 (containing 0.05percent TFA) over a period of 8 minutes. The volatiles were removed in vacuo to give a TFA salt of the title compound as white solid (0.043 g, 39percent). 1H NMR (400 MHz, DMSO-<) delta ppm 4.03 (s, 3 H), 7.60 (d, J=1.01 Hz, 1 H), 8.00 (s, 1 H), 8.34-8.52 (m, 1 H), 9.06 (s, 2 H); ESI-MS m/z [M+H]+ calc'd for Ci3H9F3N40, 295.1; found 295.15.

References: [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0783; 0784.

6
[ 1015480-87-1 ]
[ 1000342-95-9 ]
[ 76-05-1 ]
4-(3,6-dimethoxypyridazin-4-yl)-6-(trifluoromethyl)-1H-indazole trifluoroacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
4%		EXAMPLE 248 : 4-(3 ,6-dimethoxypyridazin-4-yl)-6-(trifluoromethyl)- lH-indazole [0788] A vial was charged with a mixture of 4-bromo-6-(trifluoromethyl)-lH-indazole (0.15 g, 0.566 mmol),(3,6-dimethoxypyridazin-4-yl)boronic acid (0.135 g, 0.736 mmol) and PdCl2(dppf) (0.021 g, 0.028 mmol) in dioxane (10 mL) and aqueous saturated NaHC03 (3 mL). The resulting light brown suspension was heated at 140°C for 45 minutes in a microwave reactor. The reaction mixture was subsequently concentrated and the crude residue was purified by preparative HPLC, eluting with a gradient of 40-45percent ACN (containing 0.035percent TFA) in H20 (containing 0.05percent TFA) over a period of 6.5 minutes. The volatiles were removed in vacuo to give a TFA salt of the title compound as a light brown solid (8 mg, 4percent). 1H NMR (400 MHz, DMSO-d6) delta ppm 3.97 (s, 3 H), 4.03 (s, 3 H), 7.42 (s, 1 H), 7.55 (d, J=1.01 Hz, 1 H), 8.05 (s, 1 H), 8.14 (s, 1 H), 13.74 (s, 1 H); ESI-MS m/z [M+H]+ calc'd for Ci4HiiF3N402, 325.1; found 325.16.

References: [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0787; 0788.

7
[ 1000342-95-9 ]
[ 76-05-1 ]
[ 459856-12-3 ]
4-(6-methoxy-2-methylpyridin-3-yl)-6-(trifluoromethyl)-1H-indazole trifluoroacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
47%		EXAMPLE 249: 4-(6-methoxy-2-methylpyridin-3-yl)-6-(trifluoromethyl)-lH- indazole [0790] A vial was charged with a mixture of 4-bromo-6-(trifluoromethyl)-lH-indazole (0.15 g, 0.566 mmol), (6-methoxy-2-methylpyridin-3-yl)boronic acid (0.123 g, 0.736 mmol) and PdCl2(dppf) (0.021 g, 0.028 mmol) in dioxane (10 mL) and aqueous saturated NaHC03 (3 mL). The resulting light brown suspension was heated at 140°C for 45 minutes in microwave reactor. The reaction mixture was subsequently concentrated and the crude residue was purified by preparative HPLC, eluting with 45percent ACN (containing 0.035percent) TFA) in H20 (containing 0.05percent TFA) over a period of 6.5 minutes. The volatiles were removed in vacuo to give a TFA salt of the title compound as a light brown oil (82 mg, 47percent). 1H NMR (400 MHz, OMSO-de) delta ppm 2.30 (s, 3 H), 3.93 (s, 3 H), 6.75-6.86 (m, 1 H), 7.29 (d, J=1.26 Hz, 1 H), 7.72 (d, J=8.34 Hz, 1 H), 7.90-8.03 (m, 2 H); ESI-MS m/z [M+H]+ calc'd for Ci5Hi2F3N30, 308.1; found 308.15.

References: [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0789; 0790.

8
[ 864754-16-5 ]
[ 1000342-95-9 ]
[ 76-05-1 ]
ethyl2-(4-(6-(trifluoromethyl)-1H-indazol-4-yl)-1H-pyrazol-1-yl)acetate trifluoroacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
37%		EXAMPLE 260: ethyl 2-(4-(6-(trifluoromethyl)-lH-indazol-4-yl)-lH-pyrazol-l- yl)acetate [0812] A vial was charged with a mixture of 4-bromo-6-(trifluoromethyl)-lH-indazole (0.3 g, 1.132 mmol), ethyl 2-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l- yl)acetate (0.349 g, 1.245 mmol) and PdCl2(dppf) (0.041 g, 0.057 mmol) in dioxane (10 mL) and aqueous saturated NaHC03 (3 mL). The resulting light brown suspension was heated at 140°C for 45 minutes in a microwave reactor. The reaction mixture was subsequently concentrated and the crude residue was purified by preparative HPLC, eluting with a gradient of 40-45percent ACN (containing 0.035percent TFA) in H20 (containing 0.05percent TFA) over a period of 6.5 minutes. The product-containing fractions were combined and the volatiles were removed via rotary evaporation to give a TFA salt of the title compound as a light brown solid (0.14 g, 37percent). 1H NMR (400 MHz, OMSO-d6) delta ppm 1.24 (t, J=7.07 Hz, 3 H), 4.19 (q, J=7.16 Hz, 2 H), 5.15 (s, 2 H), 7.60 (d, J=1.01 Hz, 1 H), 7.77 (s, 1 H), 8.27 (d, J=0.76 Hz, 1 H), 8.53 (s, 1 H), 8.63 (s, 1 H), 13.64 (s, 1 H); ESI-MS m/z [M+H]+ calc'd for Ci5Hi3F3N402, 339.1; found 339.

References: [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0811; 0812.

9
[ 1072945-86-8 ]
[ 1000342-95-9 ]
[ 76-05-1 ]
methyl 5-(6-(trifluoromethyl)-1H-indazol-4-yl)picolinatetrifluoroacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 269: methyl 5-(6-(trifluoromethyl)-lH-indazol-4-yl)picolinate [0830] A vial was charged with a mixture of 4-bromo-6-(trifluoromethyl)-lH-indazole (0.732 g, 2.76 mmol), (6-(methoxycarbonyl)pyridin-3-yl)boronic acid (0.5 g, 2.76 mmol) and PdCl2(dppf) (0.101 g, 0.138 mmol) in dioxane (10 mL) and aqueous saturated NaHC03 (3 mL). The resulting light brown suspension was heated at 140°C for 45 minutes in a microwave reactor. The reaction mixture was subsequently concentrated. The residue was diluted with DCM, washed with water, and the volatiles removed via rotary evaporation. The crude product was purified by CombiFlash® chromatography (0-30percent MeOH in DCM over 180 minutes). The product-containing fractions were combined and concentrated by rotary evaporation to give product with some impurities (0.28 g). A portion of the product (20 mg) was re-purified by preparative HPLC, eluting with 40percent ACN (containing 0.035percent TFA) in H20 (containing 0.05percent TFA) over a period of 6.5 minutes to give a TFA salt of the title compound. 1H NMR (400 MHz, OMSO-d6) delta ppm 3.95 (s, 3 H), 7.69 (s, 1 H), 8.07 (s, 1 H), 8.23 (dd, J=8.21, 0.63 Hz, 1 H), 8.39-8.57 (m, 2 H), 9.10-9.26 (m, 1 H), 13.86 (br s, 1 H); ESI-MS m/z [M+H]+ calc'd for Ci5Hi0F3N3O2, 322.1; found 322.11.

References: [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0829; 0830.

10
[ 1111637-69-4 ]
[ 1000342-95-9 ]
[ 76-05-1 ]
4-(3-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)-6-(trifluoromethyl)-1H-indazoletrifluoroacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
18.1%		EXAMPLE 339: 4-(3-fiuoro-lH-pyrrolo[2,3-b]pyridin-5-yl)-6-(trifluoromethyl)- lH-indazole [0970] A 20 mL microwave vial was charged with a mixture of 4-bromo-6- (trifluoromethyl)-lH-indazole (60 mg, 0.226 mmol), (3-fluoro-lH-pyrrolo[2,3-b]pyridin-5- yl)boronic acid (61.1 mg, 0.340 mmol) and PdCl2(dppf)CH2Ci2 (9.31 mg, 0.011 mmol) in dioxane (4 mL) and aqueous saturated NaHC03 (2 mL). The resulting brown suspension was heated at 130°C for 30 minutes in microwave reactor. The reaction mixture was subsequently purified by preparative HPLC, eluting with a gradient of 65-80percent acetonitrile (containing 0.035percent TFA) in H20 (containing 0.05percent TFA). The product fractions were collected and dried to give a TFA salt of the title compound as a dark purple solid (13.1 mg, 18.1percent>). 1H NMR (400 MHz, CD3OD) delta ppm 7.34 (d, J=2.27 Hz, 1 H), 7.50 (d, J=1.01 Hz, 1 H), 7.92 (s, 1 H), 8.29 (d, J=1.01 Hz, 1 H), 8.36 (d, J=2.02 Hz, 1 H), 8.62 (d, J=2.02 Hz, 1 H); ESI-MS m/z [M+H]+ calc'd for Ci5H8F4N4, 321.1; found 321.2.

References: [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0969; 0970.

11
[ 1000342-95-9 ]
[ 76-05-1 ]
[ 98-80-6 ]
4-phenyl-6-(trifluoromethyl)-1H-indazole trifluoroacetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
35%		EXAMPLE 1 : 4-phenyl-6-(trifluoromethyl)-lH-indazole [0290] A vessel was charged with 4-bromo-6-(trifluoromethyl)-lH-indazole (0.1 g, 0.377 mmol), phenylboronic acid (0.069 g, 0.566 mmol), PdCl2(dppf) (0.014 g, 0.019 mmol), and dioxane (3 mL). To the resulting slurry was added 2N aqueous sodium carbonate (0.377 mL, 0.755 mmol). The mixture was purged with nitrogen, heated in a microwave reactor at 120°C for 30 minutes, and then filtered through a pad of Celite, which was rinsed with methanol. The solvent was removed in vacuo, and the resulting residue was taken up in DMSO and methanol (1 : 1) and was purified via acidic preparative HPLC (Waters SunFire CI 8, 5muiotaeta, 30 mm ID x 75 mm column), eluting with a gradient of 55-80percent ACN (containing 0.035percent)TFA) in H20 (containing 0.05percent> TFA). The collected fractions were dried in vacuo to give a TFA salt of the title compound as a tan solid (35 mg, 35percent). 1H NMR (400 MHz, CDCls) delta ppm 7.43-7.62 (m, 4 H), 7.71 (d, J=7.07 Hz, 2 H), 7.83 (s, 1 H), 8.23-8.38 (m, 1 H), 8.47 (br s, 1 H); ESI-MS m/z [M+H]+ calc'd for C14H9F3N2, 263.1; found 263.1.

References: [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0289; 0290.

12
[ 1000342-95-9 ]
[ 73183-34-3 ]
[ 1454300-91-4 ]

Yield	Reaction Conditions	Operation in experiment
72%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate; In dimethyl sulfoxide; at 100℃; for 2h;Microwave irradiation; Sealed tube;	PREPARATION xl : 4-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)-6- (trifluoromethyl)- 1 H-indazole [0142] A mixture of 4-bromo-6-(trifluoromethyl)-lH-indazole (0.5 g, 1.887 mmol), bis(pinacolato)diboron (0.958 g, 3.77 mmol), PdCl2(dppf) (0.028 g, 0.038 mmol), and potassium acetate (0.741 g, 7.55 mmol) in DMSO (10 mL) was charged to a microwave vial, which was sealed and heated at 100°C in an oil bath for 13 hours. LCMS indicated the presence of bromide starting material, so the reaction mixture was heated for an additional 7 hours, after which LCMS showed the bromide starting material had been consumed. The reaction mixture was combined with product from an earlier run, and was subsequently partitioned between ethyl acetate (30 mL) and aqueous saturated NH4CI (30 mL). The organic phase was washed sequentially with aqueous saturated NH4C1 (30 mL) and brine (30 mL) and was dried over anhydrous sodium sulfate. The solvents were removed in vacuo, and the resulting dark brown residue was purified by silica gel chromatography (Moritex size 60 silica gel column) eluting with a gradient of 5-30percent ethyl acetate in hexanes to give the title compound as a pale yellow solid (468 mg, 72percent for two runs). ESI-MS m/z [M+H]+ calc'd for Ci4Hi6BF3N202, 313.1; found 313.2.

References: [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0141; 0142.
[2]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 2774 - 2778.

13
[ 221006-63-9 ]
[ 1000342-95-9 ]
[ 1454296-45-7 ]

Yield	Reaction Conditions	Operation in experiment
71.0%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; sodium hydrogencarbonate; In 1,4-dioxane; water; at 140℃; for 0.75h;Microwave irradiation;	EXAMPLE 263 : methyl 4-methoxy-3-(6-(trifluoromethyl)- lH-indazol-4- yl)benzoate [0818] A vial was charged with a mixture of 4-bromo-6-(trifluoromethyl)-lH-indazole (0.631 g, 2.381 mmol), (2-methoxy-5-(methoxycarbonyl)phenyl)boronic acid (0.5 g, 2.381 mmol) and PdCl2(dppf) (0.087 g, 0.119 mmol) in dioxane (10 mL) and aqueous saturated NaHCC"3 (3 mL). The resulting light brown suspension was heated at 140°C for 45 minutes in a microwave reactor. The reaction mixture was subsequently concentrated and the crude residue was diluted with DCM and washed with water, concentrated, and then purified by CombiFlash® chromatography, eluting with a gradient of 0-40percent MeOH in DCM over a period of 200 minutes. The product-containing fractions were combined and concentrated to give the title compound as a light brown solid (0.592 g, 71.0percent). 1H NMR (400 MHz, DMSO- d6) delta ppm 3.85 (s, 3 H), 3.84 (s, 3 H), 7.21-7.46 (m, 2 H), 7.89-7.99 (m, 3 H), 8.10 (dd, J=8.59, 2.27 Hz, 1 H), 13.62 (s, 1 H); ESI-MS m/z [M+H]+ calc'd for C17H13F3N2O3, 351.1; found 351.16

References: [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0817; 0818.

14
[ 1000342-95-9 ]
3-(dihydroxyboranyl)benzene-1-sulfonamide [ No CAS ]
[ 1454297-58-5 ]

Yield	Reaction Conditions	Operation in experiment
69.5%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; sodium hydrogencarbonate; In 1,4-dioxane; at 140℃; for 0.333333h;Microwave irradiation; Sealed tube;	EXAMPLE 329: 3-(6-(trifluoromethyl)-lH-indazol-4-yl)benzenesulfonamide [0950] 4-Bromo-6-(trifluoromethyl)- lH-indazole (40 mg, 0.151 mmol), (3- sulfamoylphenyl)boronic acid (45.5 mg, 0.226 mmol), PdCl2(dppf) (11.04 mg, 0.015 mmol), sodium bicarbonate (323 mu, 0.604 mmol), and dioxane were mixed in a 10 mL vial to give an orange suspension. The vial was sealed and then heated to 140°C for 20 minutes in a microwave reactor. The reaction mixture was subsequently filtered and the product was purified by preparative HPLC, eluting with a gradient of 35-70percent ACN in H20 (containing 10 mM NH4HCO3). The pure fractions were lyophilized to give the title compound as a white solid (35.8 mg, 69.5percent). 1H NMR (400 MHz, DMSO-<) delta ppm 7.50 (s, 2 H), 7.53 (s, 1 H), 7.75-7.80 (m, 1 H), 7.92-7.94 (m, 1 H), 8.02 (s, 1 H), 8.06 (dt, J=8.02, 1.29 Hz, 1H), 8.21 (t, J=1.64 Hz, 1 H), 8.40 (s, 1 H); ESI-MS m/z [M+H]+ calc'd for C14H10F3N3O2S, 342.0; found 342.2.

References: [1]Patent: WO2013/130855,2013,A1 .Location in patent: Paragraph 0949.

15
[ 913836-15-4 ]
[ 1000342-95-9 ]
[ 1454300-95-8 ]